Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 32c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.08), $0.32 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $8.8 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Towne Bank (TOWN) Reports In-Line Q1 EPS
• Kaiser Aluminum (KALU) Tops Q1 EPS by 42c